NO3057589T3 - - Google Patents

Info

Publication number
NO3057589T3
NO3057589T3 NO14726444A NO14726444A NO3057589T3 NO 3057589 T3 NO3057589 T3 NO 3057589T3 NO 14726444 A NO14726444 A NO 14726444A NO 14726444 A NO14726444 A NO 14726444A NO 3057589 T3 NO3057589 T3 NO 3057589T3
Authority
NO
Norway
Application number
NO14726444A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3057589T3 publication Critical patent/NO3057589T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14726444A 2014-05-09 2014-05-09 NO3057589T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000029 WO2015171005A1 (fr) 2014-05-09 2014-05-09 (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Publications (1)

Publication Number Publication Date
NO3057589T3 true NO3057589T3 (fr) 2017-12-30

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14726444A NO3057589T3 (fr) 2014-05-09 2014-05-09

Country Status (29)

Country Link
US (1) US9814712B2 (fr)
EP (1) EP3057589B1 (fr)
JP (1) JP6768520B2 (fr)
KR (1) KR102298676B1 (fr)
CN (1) CN106456637B (fr)
AU (1) AU2014393490B2 (fr)
CA (1) CA2948598C (fr)
CY (1) CY1119532T1 (fr)
DK (1) DK3057589T3 (fr)
EC (1) ECSP16086247A (fr)
ES (1) ES2649492T3 (fr)
HR (1) HRP20171651T1 (fr)
HU (1) HUE035071T2 (fr)
IL (1) IL248855B (fr)
LT (1) LT3057589T (fr)
MA (1) MA39447B1 (fr)
MX (1) MX368734B (fr)
NO (1) NO3057589T3 (fr)
NZ (1) NZ726132A (fr)
PH (1) PH12016502233A1 (fr)
PL (1) PL3057589T3 (fr)
PT (1) PT3057589T (fr)
RS (1) RS56591B1 (fr)
RU (1) RU2695647C2 (fr)
SA (1) SA516380264B1 (fr)
SI (1) SI3057589T1 (fr)
TN (1) TN2016000498A1 (fr)
UA (1) UA118474C2 (fr)
WO (1) WO2015171005A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413713B (zh) * 2014-05-09 2020-07-14 特克尼梅德医疗技术股份公司 用作药物的吡吲哚对映异构体的药学上可接受的盐
RS56590B1 (sr) * 2014-05-09 2018-02-28 Tecnimede Sociedade Tecnico Medicinal S A (r)-pirlindol i njegove farmaceutski prihvatljive soli za upotrebu u medicini
EP3392251A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels
EP3392250A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (fr) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-cristal de gabapentine, de kétoprofène et de lysine, compositions pharmaceutiques et leur utilisation médicale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500662A1 (fr) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005025550A1 (fr) * 2003-09-15 2005-03-24 Vectura Limited Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
CN106413713B (zh) * 2014-05-09 2020-07-14 特克尼梅德医疗技术股份公司 用作药物的吡吲哚对映异构体的药学上可接受的盐

Also Published As

Publication number Publication date
RU2016148183A (ru) 2018-06-13
PH12016502233A1 (en) 2017-02-06
MA39447A1 (fr) 2017-10-31
CN106456637A (zh) 2017-02-22
ES2649492T3 (es) 2018-01-12
LT3057589T (lt) 2017-11-27
CA2948598A1 (fr) 2015-11-12
EP3057589A1 (fr) 2016-08-24
WO2015171005A1 (fr) 2015-11-12
KR102298676B1 (ko) 2021-09-07
IL248855B (en) 2020-05-31
JP2017518979A (ja) 2017-07-13
CA2948598C (fr) 2021-06-08
MX2016014699A (es) 2017-05-02
UA118474C2 (uk) 2019-01-25
TN2016000498A1 (en) 2018-04-04
US20170143709A1 (en) 2017-05-25
US9814712B2 (en) 2017-11-14
HUE035071T2 (en) 2018-05-02
HRP20171651T1 (hr) 2017-12-15
PL3057589T3 (pl) 2018-01-31
EP3057589B1 (fr) 2017-08-02
MA39447B1 (fr) 2018-05-31
CY1119532T1 (el) 2018-03-07
RS56591B1 (sr) 2018-02-28
DK3057589T3 (da) 2017-11-13
SA516380264B1 (ar) 2019-07-29
JP6768520B2 (ja) 2020-10-14
SI3057589T1 (sl) 2017-12-29
AU2014393490A1 (en) 2016-11-24
MX368734B (es) 2019-10-14
RU2016148183A3 (fr) 2018-06-13
AU2014393490B2 (en) 2020-01-02
ECSP16086247A (es) 2017-02-24
CN106456637B (zh) 2020-06-09
NZ726132A (en) 2019-02-22
RU2695647C2 (ru) 2019-07-25
KR20170002434A (ko) 2017-01-06
IL248855A0 (en) 2017-01-31
PT3057589T (pt) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112016016301A2 (fr)
BR112016016951A2 (fr)
BR112016018070A2 (fr)
BR112016016224A2 (fr)
BR112016018327A2 (fr)
BR112016015365A2 (fr)
BR112016030558A2 (fr)
BR112016020894A2 (fr)
RU2016137525A3 (fr)
BR112016018632A2 (fr)
BR112016016403A2 (fr)
BR112016021573A2 (fr)
BR112016030543A2 (fr)
BR112016026153A2 (fr)
BR112016027741A2 (fr)
BR112016020717A2 (fr)
BR112016015776A2 (fr)
RU2016148183A3 (fr)
JP1522717S (fr)
JP1525827S (fr)
JP1519782S (fr)
BR112016015599A2 (fr)
CN302746711S (fr)
CN302705434S (fr)
CN302870780S (fr)